Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Colorectal Cancer KOL Interview - US

Published by Datamonitor Healthcare Product code 973503
Published Content info 17 Pages
Delivery time: 1-2 business days
Price
Back to Top
Colorectal Cancer KOL Interview - US
Published: October 29, 2020 Content info: 17 Pages
Description

Overview

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.

Back to Top